Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

GABA (Gamma Amino Butyric Acid) Medication for Tobacco

This study has been completed.
National Institute on Drug Abuse (NIDA)
VA Office of Research and Development
Information provided by (Responsible Party):
Mehmet Sofuoglu, Yale University Identifier:
First received: March 24, 2008
Last updated: July 7, 2015
Last verified: July 2015
The goal of this study is to examine the effects of a GABA (gamma amino butyric acid)-enhancing medication, pregabalin (300 mg/day), on smoking behavior, tobacco withdrawal and cigarette craving in smokers. We hypothesize that in smokers, pregabalin at 300 mg/day, will be more effective than placebo in decreasing smoking behavior and attenuating tobacco withdrawal and cigarette craving.

Condition Intervention Phase
Nicotine Dependence
Drug: pregabalin
Other: cigarettes
Early Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Pregabalin Given to Tobacco Users to Study Addiction

Resource links provided by NLM:

Further study details as provided by Yale University:

Primary Outcome Measures:
  • We believe this medication will help people to stop smoking [ Time Frame: 2 years ]

Enrollment: 24
Study Start Date: August 2007
Study Completion Date: February 2010
Primary Completion Date: February 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A
pregabalin 300mg/day given in conjunction with smoking cigarettes.
Drug: pregabalin
Help stop smoking
Other Name: 300mg/day for pregabalin with smoking cigarettes
Other: cigarettes
help stop smoking with study medication
Experimental: 2
cigarettes given in conjunction with pregabalin
Drug: pregabalin
Help stop smoking
Other Name: 300mg/day for pregabalin with smoking cigarettes
Other: cigarettes
help stop smoking with study medication

Detailed Description:

A total of 40 smokers will be randomly assigned to a sequence of treatment conditions: 300 mg/day pregabalin or placebo treatment. Each treatment condition will last 4 days, separated by 3 to 15 days of washout period. Smokers will have twice daily outpatient visits during the first 3 days and a test session on day 4. In each treatment period, smokers will abstain from smoking for 2.5 days, starting at 10 pm on Day 1 until the test session on Day 4. During the test sessions, measures of smoking behavior and tobacco withdrawal will be obtained.

Smoking is an important public health problem costing over 430,000 lives a year in this county alone. The first line-treatments, Nicotine Replacement Treatments (NRT) or bupropion, compared to placebo, approximately double the long-term success rate for smoking cessation. Given that there remains 46 million smokers in this country and over 70 percent of them interested in quitting smoking, development of new treatments for smoking cessation will have great public health implications.

Currently this protocol is complete with 24 completers. This study has been published. (April 2011)


Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Female and male smokers, aged 18 to 55 years
  • History of smoking daily for the past 12 months
  • at least 15 cigarettes daily
  • In good health as verified by medical history
  • screening examination
  • screening laboratory tests
  • not pregnant as determined by pregnancy screening, nor breast feeding
  • using acceptable birth control methods.

Exclusion Criteria:

  • History of pregabalin allergy
  • Use of psychotropic medication antidepressants, antipsychotics DSM-IV axis I diagnosis (schizophrenia, bipolar disorder, major depression
  • Dependence or abuse of alcohol or any other illicit or prescription drugs
  • current use of any other tobacco products, including smokeless tobacco
  • history of seizures
  • Inability to fulfill all scheduled visits and examination procedures
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00644137

United States, Connecticut
Yale University
New Haven, Connecticut, United States, 06520
Sponsors and Collaborators
Yale University
National Institute on Drug Abuse (NIDA)
VA Office of Research and Development
Principal Investigator: Mehmet Sofuoglu, M.D., Ph.D. Yale University
  More Information

Responsible Party: Mehmet Sofuoglu, Principle Investigator, Yale University Identifier: NCT00644137     History of Changes
Other Study ID Numbers: R01DA020752 ( US NIH Grant/Contract Award Number )
Yale 0701002184 ( Registry Identifier: Yale )
VA 0023 ( Registry Identifier: VA )
DPMC ( Other Identifier: NIDA )
Study First Received: March 24, 2008
Last Updated: July 7, 2015

Keywords provided by Yale University:
smoking sensations
no cravings
desire to smoke

Additional relevant MeSH terms:
Tobacco Use Disorder
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Anti-Anxiety Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs processed this record on May 24, 2017